To further test EMBER in a real world clinical setting, we used gene expression data from the POETIC trial29, a window trial, which evaluated tumor response to the aromatase inhibitors letrozole or anastrozole in postmenopausal ER+ BC patients using Ki67 index as endpoint. Here, CYP19A1 is linked to breast cancer.